SINOPHARM GROUP 1/5/O.N. (X2S1) — Cash Flow Quality Index
SINOPHARM GROUP 1/5/O.N. (X2S1) has a Cash Flow Quality Index of 1.98x as of December 2025. Operating cash flow of €14.14 Billion exceeds net income of €7.16 Billion, indicating high earnings quality where cash backs reported profits. Explore X2S1 cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
SINOPHARM GROUP 1/5/O.N. Cash Flow Quality Index (2021–2025)
Historical Cash Flow Quality Index for SINOPHARM GROUP 1/5/O.N. across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check SINOPHARM GROUP 1/5/O.N. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for SINOPHARM GROUP 1/5/O.N. (2021–2025)
Year-by-year earnings quality comparison for SINOPHARM GROUP 1/5/O.N.. For live market cap and the full company financial profile, see SINOPHARM GROUP 1/5/O.N. market cap and net worth.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.98x | €14.14 Billion | €7.16 Billion | ▲ +20.6% |
| 2024 | 1.64x | €11.55 Billion | €7.05 Billion | ▼ -13.7% |
| 2023 | 1.90x | €17.17 Billion | €9.05 Billion | ▼ -22.9% |
| 2022 | 2.46x | €20.96 Billion | €8.53 Billion | ▲ +105.0% |
| 2021 | 1.20x | €9.31 Billion | €7.76 Billion | — |